AAM applauds reintroduction of Q1/Q2 House bill
The legislation by Reps. Dunn and Mullin aims to cut red tape, expedite generic approvals, and save $800 million over a decade.
AAM
AAM says Inflation Reduction Act undermines generic and biosimilar competition
The AAM warns that IRA price controls may reduce generics and biosimilars, slowing competition and keeping drug prices high.
Industry organizations react to new tariffs imposed by Trump Administration
President Trump said Monday that he would pause tariffs on Mexico and Canada for a month, but levies on China were still set to take effect on Tuesday.
Keren Haruvi reelected chair of the AAM's board of directors
“It has been an honor to lead our AAM board and I’m excited to continue as chair,” said Keren Haruvi, president of Sandoz North America.
John Murphy named president and CEO of AAM
He most recently served as the chief policy officer at the Biotechnology Innovation Organization, where he led BIO’s legal, policy, and international initiatives for the organization’s healthcare portfolio.
